Zentek Ltd. (TSE:ZEN) has released an update.
Zentek Ltd. reports that its subsidiary Triera Biosciences Ltd. has found its COVID-19 therapeutic candidate, C19HBA, to have a favorable safety and toxicity profile in preclinical tests, indicating potential as a human therapeutic. The C19HBA aptamer, previously shown to be effective in preventing and treating SARS-CoV-2 infections, displayed no significant inflammatory response in treated mice compared to control groups.
For further insights into TSE:ZEN stock, check out TipRanks’ Stock Analysis page.
